Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at HC Wainwright

Tenaya Therapeutics (NASDAQ:TNYA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $18.00 price objective on the stock.

Several other equities analysts have also recently weighed in on TNYA. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Chardan Capital dropped their target price on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Canaccord Genuity Group restated a “buy” rating and issued a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tenaya Therapeutics has a consensus rating of “Buy” and an average target price of $14.75.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock traded up $0.37 during trading hours on Monday, reaching $2.75. 3,091,500 shares of the company’s stock traded hands, compared to its average volume of 921,765. Tenaya Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $7.01. The firm has a market capitalization of $217.86 million, a price-to-earnings ratio of -1.90 and a beta of 2.34. The firm’s 50 day moving average is $2.02 and its 200-day moving average is $2.86.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Analysts predict that Tenaya Therapeutics will post -1.35 EPS for the current year.

Institutional Trading of Tenaya Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in shares of Tenaya Therapeutics during the 3rd quarter valued at about $49,000. The Manufacturers Life Insurance Company boosted its position in shares of Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after purchasing an additional 7,000 shares in the last quarter. Algert Global LLC bought a new stake in Tenaya Therapeutics in the second quarter worth $74,000. XTX Topco Ltd lifted its holdings in shares of Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after purchasing an additional 16,687 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Tenaya Therapeutics during the third quarter valued at $134,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.